Continuous-time Markov modelling of flexible-dose depression trials

The aim of this paper is to provide a systematic methodology for modelling longitudinal data to be used in contexts of limited or even absent knowledge of the physiological mechanism underlying the disease time course. Adopting a system-theoretic paradigm, a population response model is developed where the clinical endpoint is described as a function of the patient’s health state. In particular, a continuous-time stochastic approach is proposed where the clinical score and its time-derivative summarize the patient’s health state affected by a random term accounting for exogenous unpredictable factors. The proposed approach is validated on experimental data from the placebo and drug arms of a Phase II depression trial. Since some subjects in the trial may undergo changes in their treatment dose due to the flexible dosing scheme, dose escalations are modelled as instantaneous perturbations on the state. In its simplest form—an integrated Wiener process—was able to correctly capture the individual responses in both treatment arms. However, a better description of inter-individual variability was obtained by means of a stable Markovian model. Parameter estimation has been carried out according to the empirical Bayes method.

[1]  F. Girosi,et al.  Networks for approximation and learning , 1990, Proc. IEEE.

[2]  R. Gomeni,et al.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.

[3]  Chuanpu Hu,et al.  Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  Giuseppe De Nicolao,et al.  Nonparametric Identification of Population Models: An MCMC Approach , 2008, IEEE Transactions on Biomedical Engineering.

[5]  R. Gomeni,et al.  Modelling placebo response in depression trials using a longitudinal model with informative dropout. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  Stefano Zamuner,et al.  A PCA approach to population analysis: with application to a Phase II depression trial , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[8]  R Gomeni,et al.  Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible‐Dose Trials: A Case Study in Depression , 2012, Clinical pharmacology and therapeutics.

[9]  J. L. Steimer,et al.  Variability in drug therapy : description, estimation, and control : a Sandoz workshop , 1985 .

[10]  Stefano Zamuner,et al.  Population modelling of patient responses in antidepressant studies: a stochastic approach. , 2015, Mathematical biosciences.

[11]  Giuseppe De Nicolao,et al.  Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches , 2011, IEEE Transactions on Biomedical Engineering.

[12]  Meindert Danhof,et al.  Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. , 2008, Journal of psychiatric research.

[13]  Italo Poggesi,et al.  Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity , 2009, Expert opinion on drug discovery.

[14]  D R Mould,et al.  Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.

[15]  Tomaso A. Poggio,et al.  Regularization Theory and Neural Networks Architectures , 1995, Neural Computation.

[16]  Genshiro Kitagawa,et al.  An algorithm for solving the matrix equation X = FXF T + S , 1977 .

[17]  An Vermeulen,et al.  Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders , 2011, Clinical pharmacokinetics.

[18]  Giuseppe De Nicolao,et al.  Nonparametric identification of population models via Gaussian processes , 2007, Autom..

[19]  H. Robbins.  The Empirical Bayes Approach to Statistical Decision Problems , 1964 .

[20]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[21]  A. Barraud.  ' An algorithm for solving the matrix equation X=FXFT + S' , 1978 .

[22]  Michael Krams,et al.  Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  Mark E. Sale,et al.  A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.